A-kinase interacting protein 1 mRNA (AKIP1 mRNA)

A-kinase interacting protein 1 (AKIP1) mRNA encodes a multifunctional adaptor protein, also known as breast cancer-associated protein 3 (BCA3), which is a critical regulator of protein kinase A (PKA) and nuclear factor-kappa B (NF-κB) signaling [2, 3, 11]. The AKIP1 protein facilitates the nuclear translocation of the PKA catalytic subunit and acts as a molecular scaffold to enhance NF-κB-dependent gene transcription, promoting processes such as cell proliferation, angiogenesis, and epithelial-mesenchymal transition (EMT) [3, 5, 13]. In many malignancies, including breast, lung, and thyroid cancers, AKIP1 mRNA is significantly overexpressed and correlates with poor prognosis, metastasis, and resistance to chemotherapy [1, 6, 15, 17]. Conversely, in cardiac tissues, AKIP1 plays a protective role by maintaining mitochondrial function and reducing oxidative stress during ischemia-reperfusion injury [2, 10]. While no approved drugs currently target AKIP1, experimental strategies using siRNA to knockdown AKIP1 mRNA have demonstrated the ability to restore chemosensitivity to drugs like doxorubicin and inhibit tumor progression [1, 4, 9]. Consequently, AKIP1 mRNA represents a promising therapeutic target for RNA-based interventions in oncology, though its role in cardiac protection necessitates careful consideration of potential safety profiles [2, 10, 15].

Other names

Breast cancer-associated protein 3 mRNABCA3 mRNAA kinase (PRKA) interacting protein 1 mRNAKoyt binding protein mRNA

Knockdown of AKIP1 mRNA via RNA interference (siRNA) or antisense oligonucleotides leads to reduced levels of the AKIP1 protein, which subsequently inactivates the PI3K/AKT, β-catenin, and NF-κB signaling pathways, thereby inhibiting tumor growth and restoring sensitivity to chemotherapeutic agents [1, 4, 9].